stockrowTakeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
Follow TAK
Alert me
Takeda Pharmaceutical Co. (TAK) EBITDA
Takeda Pharmaceutical Co.'s EBITDA for fiscal 2026 was $4.8B, down 34.1% from $7.3B in fiscal 2025. Over the twelve months to 30 June 2026 it was $8.3B. Over the past ten years it has ranged from $1.2B (fiscal 2015) to $28.7B (fiscal 2021); the current reading is higher than 50% of that period. Takeda Pharmaceutical Co. ranks 1st of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | $4.8B | (34.12%) |
| FY2025 | $7.3B | 12.09% |
| FY2024 | $6.5B | (23.94%) |
| FY2023 | $8.5B | (8.02%) |
| FY2022 | $9.3B | (67.67%) |
| FY2021 | $28.7B | 356.69% |
| FY2020 | $6.3B | 46.47% |
| FY2019 | $4.3B | 12.62% |
| FY2018 | $3.8B | 8.34% |
| FY2017 | $3.5B | 29.27% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $2.3B | (9.13%) |
| Jun 2025 | $2.5B | 10.11% |
| Jun 2024 | $2.3B | 88.67% |
| Mar 2024 | $1.2B | (37.63%) |
| 25 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| TAK Takeda Pharmaceutical Co. | $8.3B |
| HLN Haleon PLC Sponsored ADR compare | $4.3B |
| ZTS Zoetis Inc. compare | $4.0B |
| VTRS Viatris Inc. compare | $2.7B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $2.3B |
| UTHR United Therapeutics Corporation compare | $1.4B |
| NBIX Neurocrine Biosciences, Inc. compare | $976.5M |
| ELAN Elanco Animal Health Incorporated compare | $774.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $526.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on TAK
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement